First AREDS 2 AMD product hits market

Article

Visual Advantage by Macular Health is the first product available to the public featuring the new AREDS 2 formula for preventing vision loss due to AMD.

 

Birmingham, AL-Visual Advantage by Macular Health has become the first product available to the public featuring the new AREDS 2 formula for preventing vision loss due to AMD.

Macular Health's original supplement formulation was modeled after the results of AREDS I, released in 2001. However, Jeffery McAnnally, president and chief executive officer of Macular Health, along with John O. Mason, III, MD, a retina surgeon from the University of Alabama at Birmingham Callahan Eye Foundation Hospital, modified the formula slightly to include lutein and zeaxanthin, which were ultimately proven by AREDS 2 to be the keys to the supplement's effectiveness.

Macular Health's Visual Advantage is specially formulated in the United States by an FDA inspected and GMP (Good Manufacturing Practices) compliant facility.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.